ATE245997T1 - Therapien des chronischen nierenversagens - Google Patents
Therapien des chronischen nierenversagensInfo
- Publication number
- ATE245997T1 ATE245997T1 AT97923567T AT97923567T ATE245997T1 AT E245997 T1 ATE245997 T1 AT E245997T1 AT 97923567 T AT97923567 T AT 97923567T AT 97923567 T AT97923567 T AT 97923567T AT E245997 T1 ATE245997 T1 AT E245997T1
- Authority
- AT
- Austria
- Prior art keywords
- therapies
- chronic kidney
- kidney failure
- risk
- treatment
- Prior art date
Links
- 208000020832 chronic kidney disease Diseases 0.000 title abstract 2
- 208000022831 chronic renal failure syndrome Diseases 0.000 title abstract 2
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 abstract 3
- 102000004169 proteins and genes Human genes 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 2
- 238000011282 treatment Methods 0.000 abstract 2
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 abstract 1
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 abstract 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 abstract 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 abstract 1
- 229940112869 bone morphogenetic protein Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000002188 osteogenic effect Effects 0.000 abstract 1
- 238000012959 renal replacement therapy Methods 0.000 abstract 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Saccharide Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/643,321 US6498142B1 (en) | 1996-05-06 | 1996-05-06 | Morphogen treatment for chronic renal failure |
| PCT/US1997/007655 WO1997041880A1 (en) | 1996-05-06 | 1997-05-06 | Therapies for chronic renal failure |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE245997T1 true ATE245997T1 (de) | 2003-08-15 |
Family
ID=24580305
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT97923567T ATE245997T1 (de) | 1996-05-06 | 1997-05-06 | Therapien des chronischen nierenversagens |
| AT97922726T ATE277629T1 (de) | 1996-05-06 | 1997-05-06 | Morphogenische behandlung des chronischen nierenversagens |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT97922726T ATE277629T1 (de) | 1996-05-06 | 1997-05-06 | Morphogenische behandlung des chronischen nierenversagens |
Country Status (11)
| Country | Link |
|---|---|
| US (5) | US6498142B1 (enExample) |
| EP (2) | EP0910400B1 (enExample) |
| JP (4) | JP2000510835A (enExample) |
| AT (2) | ATE245997T1 (enExample) |
| AU (2) | AU2933997A (enExample) |
| CA (2) | CA2254954C (enExample) |
| DE (2) | DE69723845T2 (enExample) |
| DK (2) | DK0914146T3 (enExample) |
| ES (2) | ES2230604T3 (enExample) |
| PT (2) | PT910400E (enExample) |
| WO (2) | WO1997041881A1 (enExample) |
Families Citing this family (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6077823A (en) * | 1991-03-11 | 2000-06-20 | Creative Biomolecules, Inc. | Method for reducing tissue damage associated with ischemia-reperfusion or hypoxia injury |
| CA2363965C (en) * | 1991-03-11 | 2010-05-18 | Curis, Inc. | Protein-induced morphogenesis |
| US20030167492A1 (en) | 1994-07-08 | 2003-09-04 | Johns Hopkins University School Of Medicine | Transgenic non-human animals expressing a gdf-11 dominant negative polypeptide, and methods of making and using same |
| US6498142B1 (en) * | 1996-05-06 | 2002-12-24 | Curis, Inc. | Morphogen treatment for chronic renal failure |
| AU743510B2 (en) | 1997-05-05 | 2002-01-24 | Stryker Corporation | Therapies for acute renal failure |
| WO1998050061A1 (en) * | 1997-05-07 | 1998-11-12 | Biogen, Inc. | Novel therapies for cystic kidney disease |
| DE69714035T2 (de) | 1997-08-14 | 2003-03-06 | Sulzer Innotec Ag, Winterthur | Zusammensetzung und Vorrichtung zur Reparatur von Knorpelgewebe in vivo bestehend aus Nanokapseln mit osteoinduktiven und/oder chondroinduktiven Faktoren |
| US6203788B1 (en) * | 1997-09-29 | 2001-03-20 | Adherex Inc. | Compounds and methods for regulating cell adhesion |
| WO1999028341A2 (en) * | 1997-12-04 | 1999-06-10 | Creative Biomolecules, Inc. | Maintenance of smooth muscle integrity by morphogenic proteins |
| NZ509609A (en) * | 1998-07-28 | 2003-11-28 | Univ Johns Hopkins Med | Disrupting growth differentiation factor-11 (GDF-11) to increase the muscle and bone tissue in animals |
| US7087577B2 (en) * | 1998-10-16 | 2006-08-08 | Zimmer Orthobiologies, Inc. | Method of promoting natural bypass |
| US6992066B2 (en) | 1998-10-16 | 2006-01-31 | Zimmer Orthobiologics, Inc. | Povidone-containing carriers for polypeptide growth factors |
| EP1214091B1 (en) * | 1999-09-14 | 2006-05-10 | Biogen Idec MA Inc. | Therapies for chronic renal failure using one or more integrin antagonists |
| US20020173453A1 (en) * | 2000-12-15 | 2002-11-21 | Rama Akella | Method of treating renal injury |
| US7763769B2 (en) | 2001-02-16 | 2010-07-27 | Kci Licensing, Inc. | Biocompatible wound dressing |
| US7700819B2 (en) | 2001-02-16 | 2010-04-20 | Kci Licensing, Inc. | Biocompatible wound dressing |
| US7232802B2 (en) | 2001-12-21 | 2007-06-19 | Zimmer Orthobiologics, Inc. | Compositions and methods for promoting myocardial and peripheral angiogenesis |
| US7622562B2 (en) | 2002-06-26 | 2009-11-24 | Zimmer Orthobiologics, Inc. | Rapid isolation of osteoinductive protein mixtures from mammalian bone tissue |
| WO2004019876A2 (en) * | 2002-08-28 | 2004-03-11 | Curis, Inc. | Conjoint administration of morphogens and ace inhibitors in treatment of chronic renal failure |
| DK1677735T3 (da) | 2003-10-17 | 2014-10-27 | Joslin Diabetes Center Inc | Fremgangsmåder og sammensætninger til modulering af adipocytfunktion |
| US7844367B2 (en) | 2003-12-23 | 2010-11-30 | Rain Bird Corporation | Code replacement for irrigation controllers |
| KR101153035B1 (ko) * | 2004-03-30 | 2012-06-11 | 리립사, 인크. | 이온 결합 조성물 |
| CA2561809A1 (en) * | 2004-03-31 | 2005-10-20 | Xencor, Inc. | Bmp-7 variants with improved properties |
| US20100150885A1 (en) * | 2005-06-01 | 2010-06-17 | Joslin Diabetes Center, Inc. | Methods and compositions for inducing brown adipogenesis |
| US7771995B2 (en) * | 2005-11-14 | 2010-08-10 | Merial Limited | Plasmid encoding human BMP-7 |
| EP1951751B1 (en) * | 2005-11-14 | 2017-11-01 | Merial, Inc. | Gene therapy for renal failure |
| EP1978802A2 (en) * | 2006-01-24 | 2008-10-15 | Northfield Laboratories, Inc. | Polymerized hemoglobin media and its use in isolation and transplantation of islet cells |
| US20090004159A1 (en) * | 2006-01-24 | 2009-01-01 | The Board Of Trustees Of The University Of Illinoi | Polymerized Hemoglobin Media and Its Use in Isolation and Transplantation of Islet Cells |
| US20080090765A1 (en) * | 2006-05-25 | 2008-04-17 | The Trustees Of Columbia University In The City Of New York | Compositions for modulating growth of embryonic and adult kidney tissue and uses for treating kidney damage |
| PL2035835T3 (pl) | 2006-05-30 | 2012-05-31 | Antibodyshop As | Sposoby szybkiej oceny ciężkości urazu |
| US7722665B2 (en) * | 2006-07-07 | 2010-05-25 | Graft Technologies, Inc. | System and method for providing a graft in a vascular environment |
| EP2047862B9 (en) * | 2006-07-21 | 2013-04-10 | Chugai Seiyaku Kabushiki Kaisha | Remedy for renal disease |
| WO2008075173A2 (en) * | 2006-12-15 | 2008-06-26 | Ruprecht-Karls-Universität Heidelberg | Methods for treating podocyte-related disorders |
| WO2008134297A2 (en) * | 2007-04-24 | 2008-11-06 | Johnson & Johnson Regenerative Therapeutics, Llc | Engineered renal tissue |
| DE102007034580B4 (de) * | 2007-07-13 | 2012-11-08 | NMI Naturwissenschaftliches und Medizinisches Institut an der Universität Tübingen | Biomaterial basierend auf einem hydrophilen polymeren Träger |
| US20090155245A1 (en) * | 2007-12-18 | 2009-06-18 | Fang Carrie H | Treatment for Organ Regeneration with Combination of Drug and Biologics |
| WO2009137613A2 (en) * | 2008-05-06 | 2009-11-12 | Joslin Diabetes Center, Inc. | Methods and compositions for inducing brown adipogenesis |
| WO2009157165A1 (ja) * | 2008-06-24 | 2009-12-30 | 株式会社根本杏林堂 | 薬液注入装置、この薬液注入装置を有する透視撮像システム、薬液注入装置のコンピュータプログラムおよびデータ処理方法 |
| JP2012501456A (ja) * | 2008-08-28 | 2012-01-19 | アスチュート メディカル，インコーポレイテッド | 腎損傷および腎不全の診断および予後のための方法および組成物 |
| CA2735590A1 (en) * | 2008-08-29 | 2010-03-04 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| WO2010048346A1 (en) | 2008-10-21 | 2010-04-29 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| EP2767833A3 (en) * | 2008-10-21 | 2014-12-17 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| CN104330574B (zh) | 2008-11-10 | 2017-04-12 | 阿斯图特医药公司 | 用于诊断和预后肾损伤和肾衰竭的方法和组合物 |
| EP2364370B1 (en) * | 2008-11-22 | 2014-09-03 | Astute Medical, Inc. | Methods for prognosis of acute renal failure |
| CN102369293B (zh) * | 2009-02-06 | 2014-05-28 | 阿斯图特医药公司 | 肾损伤和肾衰竭的诊断及预后 |
| US9229010B2 (en) | 2009-02-06 | 2016-01-05 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| EP2396026A2 (en) * | 2009-02-12 | 2011-12-21 | Stryker Corporation | Compositions and methods for minimally-invasive systemic delivery of proteins including tgf- superfamily members |
| US20100204123A1 (en) | 2009-02-12 | 2010-08-12 | Mary Elizabeth Pecquet Goad | Peripheral Administration of Proteins Including TGF-beta Superfamily Members for Treatment of Systemic Disorders and Disease |
| AU2010223268B2 (en) * | 2009-03-12 | 2015-04-23 | Haase Investments Gmbh | Bone morphogenetic protein 2 (BMP2 ) variants with reduced BMP antagonist sensitivity |
| US20110002897A1 (en) | 2009-06-11 | 2011-01-06 | Burnham Institute For Medical Research | Directed differentiation of stem cells |
| KR20120061863A (ko) | 2009-08-07 | 2012-06-13 | 아스튜트 메디컬 인코포레이티드 | 신장 손상 및 신부전증의 진단과 예후를 위한 방법 및 조성물 |
| EP2352750B1 (en) | 2009-09-17 | 2012-06-13 | Stryker Corporation | Buffers for controlling the ph of bone morphogenetic proteins |
| MX340078B (es) | 2009-11-07 | 2016-06-24 | Astute Medical Inc | Metodos y composiciones para el diagnostico y pronostico de daño renal y falla renal. |
| MX342967B (es) | 2009-12-20 | 2016-10-19 | Astute Medical Inc | Metodos y composiciones para la diagnosis y prognosis de lesion renal y falla renal. |
| CA2785038A1 (en) | 2009-12-22 | 2011-07-21 | Stryker Corporation | Bmp-7 variants with reduced immunogenicity |
| CN102791885B (zh) | 2010-02-05 | 2015-09-09 | 阿斯图特医药公司 | 用于肾损伤和肾衰竭的诊断及预后的方法和组合物 |
| EP2539712A4 (en) | 2010-02-26 | 2013-09-18 | Astute Medical Inc | METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE |
| JP2013529907A (ja) | 2010-05-24 | 2013-07-25 | ザ トラスティーズ オブ コロンビア ユニヴァーシティ イン ザ シティ オブ ニューヨーク | Ｎｇａｌタンパク質変異体及びその使用 |
| NZ605698A (en) | 2010-06-23 | 2015-03-27 | Astute Medical Inc | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| IN2012MN02812A (enExample) | 2010-06-23 | 2015-05-22 | Astute Medical Inc | |
| US9688735B2 (en) | 2010-08-20 | 2017-06-27 | Wyeth Llc | Designer osteogenic proteins |
| PH12013500294A1 (en) | 2010-08-20 | 2017-08-23 | Wyeth Llc | Designer osteogenic proteins |
| EP3540440B1 (en) | 2011-12-08 | 2022-09-28 | Astute Medical, Inc. | Methods and uses for evaluating renal injury and renal status |
| ES3059226T3 (en) | 2012-10-08 | 2026-03-19 | Vifor Int Ltd | Potassium-binding agents for treating hypertension and hyperkalemia |
| EP2925337B1 (en) | 2012-11-21 | 2019-07-03 | The Trustees of Columbia University in the City of New York | Mutant ngal proteins and uses thereof |
| JP6681195B2 (ja) | 2013-01-17 | 2020-04-15 | アスチュート メディカル，インコーポレイテッド | 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物 |
| US8956829B2 (en) | 2013-01-25 | 2015-02-17 | Warsaw Orthopedic, Inc. | Human recombinant growth and differentiaton factor-5 (rhGDF-5) |
| US9169308B2 (en) | 2013-01-25 | 2015-10-27 | Warsaw Orthopedic, Inc. | Methods and compositions of human recombinant growth and differentiation factor-5 (rhGDF-5) isolated from inclusion bodies |
| US9051389B2 (en) | 2013-01-25 | 2015-06-09 | Warsaw Orthopedic, Inc. | Expression conditions and methods of human recombinant growth and differentiation factor-5 (rhGDF-5) |
| US9359417B2 (en) | 2013-01-25 | 2016-06-07 | Warsaw Orthopedic, Inc. | Cell cultures and methods of human recombinant growth and differentiaton factor-5 (rhGDF-5) |
| US8945872B2 (en) | 2013-01-25 | 2015-02-03 | Warsaw Orthopedic, Inc. | Methods of purifying human recombinant growth and differentiation factor-5 (rhGDF-5) protein |
| EP2784083A1 (en) | 2013-03-28 | 2014-10-01 | Charité - Universitätsmedizin Berlin | Bone Morphogenetic Protein (BMP) variants with highly reduced antagonist sensitivity and enhanced specific biological activity |
| EP3069149B1 (en) * | 2013-11-11 | 2022-05-18 | General Electric Company | Method for reducing error in rotor speed measurements |
| EP2944326B1 (en) | 2014-05-16 | 2018-11-21 | Cyanagen Srl | Tricarbocyanine-cyclodextrin-conjugates and their use for the diagnosis of kidney diseases |
| US11241505B2 (en) | 2015-02-13 | 2022-02-08 | Factor Bioscience Inc. | Nucleic acid products and methods of administration thereof |
| AU2017277305A1 (en) | 2016-06-06 | 2018-12-20 | Astute Medical, Inc. | Management of acute kidney injury using insulin-like growth factor-binding protein 7 and tissue inhibitor of metalloproteinase 2 |
| IL264439B2 (en) | 2016-08-17 | 2024-08-01 | Factor Bioscience Inc | non-viral, cell-free composition comprising a synthetic messenger RNA (MRNA) encoding a gene-editing protein for use in treating cancer, and a synthetic RNA encoding a gene-editing protein for use in treatment |
| JP2019039673A (ja) * | 2017-08-22 | 2019-03-14 | セイコーエプソン株式会社 | 時間デジタル変換回路、回路装置、物理量測定装置、電子機器及び移動体 |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1156741B (it) * | 1978-05-15 | 1987-02-04 | Sigma Tau Ind Farmaceuti | Applicazione terapeutica della carnitina e di alcuni derivati acilati della carnitina nell'emodialisi |
| US4342828A (en) | 1979-07-20 | 1982-08-03 | Morinaga Milk Industry Co., Ltd. | Method for producing substance capable of stimulating differentiation and proliferation of human granulopoietic stem cells |
| US4627839A (en) * | 1985-11-21 | 1986-12-09 | American Hospital Supply Corporation | Patient controlled analgesia conversion |
| IL83003A (en) | 1986-07-01 | 1995-07-31 | Genetics Inst | Osteoinductive factors |
| US5013649A (en) * | 1986-07-01 | 1991-05-07 | Genetics Institute, Inc. | DNA sequences encoding osteoinductive products |
| US5266683A (en) * | 1988-04-08 | 1993-11-30 | Stryker Corporation | Osteogenic proteins |
| US5011691A (en) * | 1988-08-15 | 1991-04-30 | Stryker Corporation | Osteogenic devices |
| US5045452A (en) * | 1988-09-02 | 1991-09-03 | Brigham And Women's Hospital | Method for evaluating nephrotoxicity |
| ATE162223T1 (de) | 1989-03-28 | 1998-01-15 | Genetics Inst | Osteoinduktive zusammensetzungen |
| CA2082941A1 (en) | 1990-05-16 | 1991-11-17 | Rodney M. Hewick | Bone and cartilage inductive proteins |
| JPH0426624A (ja) * | 1990-05-18 | 1992-01-29 | Tsumura & Co | 慢性腎不全改善剤 |
| ATE146076T1 (de) | 1990-06-22 | 1996-12-15 | Du Pont | Behandlung des chronischen nierenversagens mit imidazol-angiotensin-ii-rezeptorantagonisten |
| US6077823A (en) * | 1991-03-11 | 2000-06-20 | Creative Biomolecules, Inc. | Method for reducing tissue damage associated with ischemia-reperfusion or hypoxia injury |
| CA2363965C (en) * | 1991-03-11 | 2010-05-18 | Curis, Inc. | Protein-induced morphogenesis |
| US5849686A (en) * | 1991-03-11 | 1998-12-15 | Creative Biomolecules, Inc. | Morphogen-induced liver regeneration |
| US7056882B2 (en) * | 1991-03-11 | 2006-06-06 | Curis, Inc. | Treatment to prevent loss of and/or increase bone mass in metabolic bone diseases |
| US6194376B1 (en) * | 1991-03-11 | 2001-02-27 | Creative Biomolecules, Inc. | Method for modulating inflammatory response comprising administering morphogen |
| DK0575555T3 (da) | 1991-03-11 | 2001-11-05 | Curis Inc | Proteininduceret morfogenese |
| US6287816B1 (en) | 1991-06-25 | 2001-09-11 | Genetics Institute, Inc. | BMP-9 compositions |
| DE69231062T3 (de) | 1991-08-30 | 2004-07-29 | Creative Biomolecules, Inc., Hopkinton | Morphogen-induzierte Modulation von entzündlichen Antworten |
| EP1637156A1 (en) | 1991-08-30 | 2006-03-22 | Curis, Inc. | Systemic administration of osteogenic proteins in the treatment of metabolic bone diseases |
| ATE197611T1 (de) | 1991-08-30 | 2000-12-15 | Creative Biomolecules Inc | Screeningverfahren von morphogenischen proteinen |
| US6120760A (en) * | 1992-02-12 | 2000-09-19 | Biopharm Gesellschaft Zur Biotechnologischen Entwicklung | Growth/differentiation factors of the TGF-β family |
| EP0661933B1 (en) | 1992-07-31 | 1998-04-22 | Creative Biomolecules, Inc. | Morphogen-enriched dietary composition |
| AU681594B2 (en) | 1992-07-31 | 1997-09-04 | Stryker Corporation | Morphogen-induced nerve regeneration and repair |
| WO1994003600A1 (en) | 1992-07-31 | 1994-02-17 | Creative Biomolecules, Inc. | Morphogenic protein soluble complex and composition thereof |
| CA2144514C (en) | 1992-09-16 | 2002-03-26 | Thangavel Kuberasampath | Morphogen-induced liver regeneration |
| WO1994010203A2 (en) | 1992-11-03 | 1994-05-11 | Creative Biomolecules, Inc. | Op-3-induced morphogenesis |
| US5372335A (en) | 1992-12-18 | 1994-12-13 | Scott H. Yenzer | Aerial marker ball and method of placement |
| CA2157387C (en) | 1993-03-04 | 1998-12-15 | David C. Rueger | Method and compositions for recombinant osteogenic protein production |
| US5631159A (en) | 1993-09-22 | 1997-05-20 | Creative Biomolecules, Inc. | Lipid-modified serum free media |
| US5585237A (en) | 1993-10-25 | 1996-12-17 | Creative Biomolecules, Inc. | Methods and compositions for high protein production from recombinant DNA |
| AU690941B2 (en) * | 1993-11-15 | 1998-05-07 | Celtrix Pharmaceuticals, Inc. | Method of treating renal disease by administering IGF-I and IGFBP-3 |
| US5525621A (en) * | 1994-05-20 | 1996-06-11 | Cytos Pharmaceuticals Llc | Imidazole derivatives as protective agents in reperfusion injury and severe inflammatory responses |
| US5714511A (en) * | 1995-07-31 | 1998-02-03 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Selective prevention of organ injury in sepsis and shock using selection release of nitric oxide in vulnerable organs |
| US5723411A (en) * | 1995-10-31 | 1998-03-03 | E. I. Du Pont De Nemours And Company | Herbicidal pyridazinones |
| ATE493141T1 (de) * | 1996-03-22 | 2011-01-15 | Stryker Corp | Verfahren zur verbesserten funktionellen erholung der motorischen koordiination, der sprache oder der sinneswahrnehmung nach trauma oder ischämie des zns |
| US5820589A (en) * | 1996-04-30 | 1998-10-13 | Medtronic, Inc. | Implantable non-invasive rate-adjustable pump |
| US6498142B1 (en) * | 1996-05-06 | 2002-12-24 | Curis, Inc. | Morphogen treatment for chronic renal failure |
| US5879908A (en) * | 1997-04-30 | 1999-03-09 | Smithkline Beecham Corporation | CRFG-1a, a target and marker for chronic renal failure |
| US7147839B2 (en) * | 1998-05-29 | 2006-12-12 | Curis, Inc. | Methods for evaluating tissue morphogenesis and activity |
-
1996
- 1996-05-06 US US08/643,321 patent/US6498142B1/en not_active Expired - Lifetime
-
1997
- 1997-05-06 JP JP09540150A patent/JP2000510835A/ja active Pending
- 1997-05-06 AU AU29339/97A patent/AU2933997A/en not_active Abandoned
- 1997-05-06 PT PT97923567T patent/PT910400E/pt unknown
- 1997-05-06 DE DE69723845T patent/DE69723845T2/de not_active Expired - Lifetime
- 1997-05-06 ES ES97922726T patent/ES2230604T3/es not_active Expired - Lifetime
- 1997-05-06 DK DK97922726T patent/DK0914146T3/da active
- 1997-05-06 DE DE69730966T patent/DE69730966T2/de not_active Expired - Lifetime
- 1997-05-06 CA CA002254954A patent/CA2254954C/en not_active Expired - Fee Related
- 1997-05-06 WO PCT/US1997/007816 patent/WO1997041881A1/en not_active Ceased
- 1997-05-06 JP JP54021197A patent/JP4766722B2/ja not_active Expired - Fee Related
- 1997-05-06 AT AT97923567T patent/ATE245997T1/de not_active IP Right Cessation
- 1997-05-06 ES ES97923567T patent/ES2203803T3/es not_active Expired - Lifetime
- 1997-05-06 PT PT97922726T patent/PT914146E/pt unknown
- 1997-05-06 US US08/851,628 patent/US6861404B1/en not_active Expired - Fee Related
- 1997-05-06 EP EP97923567A patent/EP0910400B1/en not_active Expired - Lifetime
- 1997-05-06 EP EP97922726A patent/EP0914146B1/en not_active Expired - Lifetime
- 1997-05-06 AT AT97922726T patent/ATE277629T1/de active
- 1997-05-06 DK DK97923567T patent/DK0910400T3/da active
- 1997-05-06 WO PCT/US1997/007655 patent/WO1997041880A1/en not_active Ceased
- 1997-05-06 CA CA002254953A patent/CA2254953C/en not_active Expired - Fee Related
- 1997-05-06 AU AU28322/97A patent/AU2832297A/en not_active Abandoned
-
2004
- 2004-12-17 US US11/016,499 patent/US7524817B2/en not_active Expired - Fee Related
-
2009
- 2009-03-16 US US12/404,559 patent/US8017580B2/en not_active Expired - Fee Related
- 2009-05-26 JP JP2009126963A patent/JP5247593B2/ja not_active Expired - Fee Related
-
2011
- 2011-08-11 US US13/207,584 patent/US8377878B2/en not_active Expired - Fee Related
-
2012
- 2012-08-14 JP JP2012179876A patent/JP2012229268A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69723845D1 (de) | Therapien des chronischen nierenversagens | |
| TR199802421T2 (xx) | Doku yenilenmesini d�zenleyen maddeler. | |
| MXPA03011386A (es) | Proteina de union para su uso en la regeneracion de hueso o cartilago. | |
| UA88440C2 (ru) | ЛЕЧЕНИЕ ГЛОМЕРУЛОНЕФРИТА И ХРОНИЧЕСКОЙ ПОЧЕЧНОЙ НЕДОСТАТОЧНОСТИ ПРИ ПОМОЩИ ИНТЕРФЕРОНА-β | |
| ATE278414T1 (de) | Therapien zur behandlung von akutem nierenversagen | |
| IS2925B (is) | Ákvörðun á batahorfum sjúklings sem undirgengst meðhöndlun við Alzheimer-sjúkdómi | |
| FI960809L (fi) | Hermoregeneraatio käyttäen ihmisen luun morfogeneettisiä proteiineja | |
| EP0828519A4 (en) | Recombinant viral vector system | |
| NO982436D0 (no) | Apparat for oppvarming av blod | |
| DK52089D0 (da) | Middel til behandling af nyresygdomme | |
| SE8501050D0 (sv) | Biologically active fragments of human antihemophilic factor and method for preparation thereof | |
| PL316449A1 (en) | Combinations of thrombolytically active proteins and coagulants and their application | |
| SE8902532D0 (sv) | Bestaemning av plasmaproteiner | |
| DE69825625D1 (de) | Aminobiguanide und ihre verwendung zur desinfektion von kontaktlinsen und konservierung von pharmazeutischen zubereitungen | |
| DE69714451D1 (de) | Prionbindende proteine und deren verwendungen | |
| EP1169058A4 (en) | INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN-4 Protease | |
| EP0960117A4 (en) | ON FIBROBLASTS GROWTH FACTOR HOMOLOGICAL FACTORS (FHFs) AND METHOD OF APPLICATION | |
| HUP9801214A2 (hu) | Lecitin-koleszterin acil-transzferázt kifejező rekombináns vírusok és génterápiában való felhasználásuk | |
| NO973292D0 (no) | On-line medikamentleveringssystem i ekstrakorporeal terapi | |
| EP1185283A4 (en) | NEW THERAPEUTIC USE OF A VIRAL INJECTION MODULATING PROTEIN TO PREVENT EXHAUST FROM FOREIGN TRANSPLANTS | |
| DK1214091T3 (da) | Terapier til kronisk nyresvigt under anvendelse af én eller flere integrinantagonister | |
| FR2764389B1 (fr) | Utilisation de venin de crotalus viridis helleri, procede et necessaire pour la determination de la reactivite de la proteine c activee | |
| DE69614577D1 (de) | Polyamin-antagonisten enthaltende intraokulare irrigationslösung | |
| DE59805440D1 (de) | Verwendung von lbp zur sepsistherapie | |
| DE59609353D1 (de) | Mittel zur subkutanen Verabreichung von Protein C |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |